Category: Medicine
FDA Approves Botanix Pharmaceuticals’ Sofdra for the Treatment of Primary Axillary Hyperhidrosis
Approval of Sofdra marks the first chemical entity to be approved by the FDA to treat primary axillary hyperhidrosis.
Aidoc AI Software Used to Reduce Missed Follow Up Appointments
The company announced updates to its software to focus on this issue.
Pharma Pulse 6/21/24: Improving Access to Trials Through Decentralization & Flexible Design, South Africa Runs Out of Insulin Pens & more
The latest news for pharma industry insiders.
Preventing Bias in AI: Q&A with Michael Armstrong
The CTO of Authenticx discusses preventing bias from becoming part of AI models.
FDA Expands Approval of Sarepta Therapeutics’ Elevidys for the Treatment of Duchenne Muscular Dystrophy
Expansion of Elevidys includes patients over the age of four years with Duchenne muscular dystrophy regardless of their ambulatory status.
Phase III Trial Data Show Lenacapavir Demonstrated 100% Efficacy Preventing HIV in Cisgender Women
Results of the PURPOSE 1 trial indicated that a twice-yearly injection of lenacapavir outperformed the once-daily oral Truvada preventing HIV in cisgender women.
Beyond the Numbers: Extrapolating Today’s Trends Forward
Q&A with Evaluate’s Paul Verdin digs deeper into the data-backed drivers likely to sway the future growth and jockeying of biopharma’s top players.
Novel Therapy Shows Significant Promise Slowing Parkinson Disease Progression
Data from an early phase trial published in Nature found that Parkinson disease patients treated with UB-312 experienced significant improvements in motor functions and daily [more…]
Utilizing Biomarkers to Develop First-in-Class Antibody Drug Conjugates to Treat Advanced Solid Tumors
In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses using novel cancer biomarkers [more…]
FDA Approves AbbVie’s Skyrizi for the Treatment of Adults with Moderate to Severely Active Ulcerative Colitis
Approval of Skyrizi marks the first IL-23 specific inhibitor approved for both ulcerative colitis and Crohn disease of similar severity, according to AbbVie.